Stonefly news
- 10/01/08 - inVentiv Health Selected to Provide Integrated Marketing Services for GeneraMedix Inc.
- 9/23/08 - Stonefly Communications Group and Strategyx, LLC Win Strategic Assignment with GeneraMedix Inc.
- 8/7/08 - President and CEO of Stonefly Communications Group Receives Industry Honor
- 7/10/08 - Stonefly Communications Group Wins Assignment with Life Line Screening
- 7/17/08 - Stonefly Communications Group Serves Up "It's Launch Time!"
- 6/6/08 - Stonefly Welcomes New Members
- 5/1/08 - Stonefly Communications Group Launches New Ad Campaign
- 4/12/08 - Stonefly Wins Five-Year Agency-of-Record Assignment with Patheon
- 2/1/08 - Stonefly Wins Three-Year Agency-of-Record Assignment for Leading Global Medical Food Manufacturer
- 1/7/08 - Stonefly Communications Group Honored at RX Club Show
- 1/7/08 - Stonefly Communications Honored at 2007 Global Awards
- 2/7/07 – Stonefly Wins Assignment with ZymoGenetics' RECOTHROM™
| 2/7/07 – Stonefly Wins Assignment with ZymoGenetics' RECOTHROM™ |
|
Agency Will Lead Professional Advertising and Promotion Columbus, Ohio – February 7, 2007 – Stonefly Communications Group, an inVentiv Health company (NASDAQ:VTIV) and a purpose-driven, patient focused healthcare advertising agency, announces it has been selected by ZymoGenetics to lead the marketing and promotion of RECOTHROM. RECOTHROM is the first and only recombinant, plasma-free thrombin approved for surgical use. Recently approved by the FDA, RECOTHROM is indicated as an aid to hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques is ineffective or impractical. With thrombin being used in more than one million surgeries each year in the United States, RECOTHROM gives surgeons the opportunity to provide their patients with a plasma-free thrombin alternative for surgical hemostasis. "We are thrilled to be working with such a great team at ZymoGenetics," said John Racik, president and CEO of Stonefly Communications Group. "With the recent FDA approval of RECOTHROM, many patients and surgeons will be able to benefit from this plasma-free alternative. We are very pleased to be putting our team's skill and experience to work for such an important new product." "We are excited to work with Stonefly. Their unique marketing experience is a great complement to our team's capabilities,” said Cheryl Birch Hostinak, marketing director at ZymoGenetics. "As the first and only recombinant thrombin for surgical hemostasis, RECOTHROM shows great promise. We look forward to partnering with Stonefly to drive product growth to the next level.” ZymoGenetics creates novel protein drugs with the potential to significantly help patients fight their diseases. The company has a diverse pipeline of products moving into and through clinical development. These candidates span a wide array of clinical opportunities that include bleeding, autoimmune and viral diseases and cancer. For further information, visit www.zymogenetics.com. About Stonefly Communications Group Headquartered in Columbus, Ohio, Stonefly Communications Group is a purpose-driven, patient focused healthcare advertising agency. For more information on Stonefly Communications Group, visit www.stoneflygroup.com, or call 1-87-STONEFLY. About inVentiv Health inVentiv Health, Inc. (NASDAQ: VTIV) is an insights-driven global healthcare leader that provides dynamic solutions to deliver customer and patient success. inVentiv delivers its customized clinical, sales, marketing and communications solutions through its four core business segments: inVentiv Clinical, inVentiv Communications, inVentiv Commercial, and inVentiv Patient Outcomes. inVentiv Health's client roster is composed of more than 275 leading pharmaceutical, biotech, life sciences and healthcare payor companies, including all top 20 global pharmaceutical manufacturers. For more information, visit www.inventivhealth.com. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors. |
